Developer docs
API playgroundTry for free, no card

Search company profiles

Arcus Biosciences

Full company profile

uuid0002lig

Namestring
Arcus Biosciences
Legal namestring
Arcus Biosciences, Inc.
Websiteurl
arcusbio.com
Company typeenum
Public
Founded yearint
2015
Descriptiontext

Arcus Biosciences is a clinical-stage biopharmaceutical company headquartered in Hayward, California, founded in 2015 by Terry Rosen (CEO) and Juan Jaen (President). The company discovers and develops small-molecule inhibitors and monoclonal antibodies targeting cancer biology, with a stated emphasis on rational, biology-driven combination therapies across mechanisms including HIF-2α inhibition (casdatifan), Fc-silent anti-TIGIT (domvanalimab), adenosine axis antagonism (etrumadenant, quemliclustat), anti-PD-1 (zimberelimab), anti-CD39 (AB598), and AXL inhibition (AB801). Arcus employs 501-1,000 people, trades on the NYSE under ticker RCUS, and is expanding an early-stage inflammation and immunology portfolio (AB102/MRGPRX2, TNF inhibitor, CCR6 antagonist, anti-CD89).

The company has no approved products and generates revenue almost entirely from collaboration agreements rather than product sales. Its 2020 collaboration with Gilead Sciences — expanded via a $320 million Gilead equity investment in January 2024 that raised Gilead's stake to 33% — provides co-promotion rights in the US and ex-US commercialization rights for several programs. Taiho Pharmaceutical holds regional rights in Japan and certain Asian territories (excluding China), and AstraZeneca sponsors the registrational PACIFIC-8 Phase 3 trial in Stage 3 NSCLC. Two Phase 3 TIGIT failures (STAR-221 in December 2024 and STAR-121 in April 2026) have triggered a strategic reset: Gilead elected not to make an option continuation payment, prompting a partial rollback of the 2020 collaboration, a ~10% workforce reduction, and a R&D pivot toward casdatifan and inflammation/immunology programs. FY2025 collaboration revenue was $247 million, with cash of approximately $1.0 billion and stated runway into 2H 2028.

Strategically, Arcus is repositioning around casdatifan, supported by a 45% confirmed ORR and 15.1-month median progression-free survival in late-line kidney cancer and a Goldman Sachs risk-adjusted peak sales estimate of $1.7 billion in clear cell RCC. A new Bristol-Myers Squibb clinical collaboration (June 2026) combines casdatifan with pumitamig in RCC. Capital formation in 2025 — a $150 million public offering in February and a $250 million public offering in October — combined with a $250 million Hercules Capital term loan facility (August 2024, $50M drawn at close) funds Phase 3 execution. The company's competitive position rests on differentiated molecular design (notably Fc-silent TIGIT and HIF-2α chemistry), a leadership team with deep prior pharma R&D experience, and a partner ecosystem with Gilead, Taiho, AstraZeneca, and BMS; its principal risks are TIGIT program failures, revenue concentration on Gilead, and execution risk on casdatifan pivotal trials.

Short descriptiontext

Arcus Biosciences is a clinical-stage biopharmaceutical company developing small-molecule and antibody cancer therapies — including casdatifan, domvanalimab, and adenosine-axis inhibitors — for oncology patients, with global development and commercialization through partnerships with Gilead, Taiho, AstraZeneca, and BMS.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersHayward, United States
HQ citystring
Hayward
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cancer immunotherapy, monoclonal antibody therapy, small molecule inhibitors, immuno-oncology drugs, clinical-stage biopharmaceuticals
Industry3 codes
PRIMARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAAAK
Therapeutic Enzymes & Enzyme Replacement Therapies (ERT)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
Product category
Immuno-Oncology Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Collaboration Revenue
TypeLicensing Royalties
Description

Revenue from Gilead Sciences collaboration, including $320M equity investment and potential milestone payments. The company reported $247M full-year 2025 revenues driven primarily by its collaboration with Gilead.

pharmiweb.com
2Licensing and Milestone Payments
TypeLicensing Royalties
Description

Revenue from licensing agreements including Taiho Pharmaceutical exercising option for exclusive license to casdatifan in Japan and Asia, with potential payments and royalties.

in.investing.com
3Future Product Sales
TypeSubscription Recurring
Description

Once approved, the company will commercialize products directly in the US (with Gilead co-promotion rights) and through partners internationally.

arcusbio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Arcus Biosciences is a clinical-stage biopharmaceutical company that discovers, develops, and intends to commercialize novel small molecule inhibitors and monoclonal antibodies for the treatment of cancer. Its pipeline is built around multiple differentiated mechanisms, including Fc-silent anti-TIGIT antibodies, HIF-2α inhibition, adenosine axis blockade (A2a/A2b antagonism and CD73 inhibition), anti-PD-1, anti-CD39, and AXL inhibition, with an emerging inflammation and immunology portfolio.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Arcus Biosciences is a clinical-stage biopharmaceutical company developing best-in-class molecules and combination therapies for cancer treatment. The company's clinical pipeline includes multiple investigational candidates: domvanalimab (Fc-silent anti-TIGIT antibody), quemliclustat (CD73 inhibitor), etrumadenant (A2a/A2b adenosine receptor antagonist), zimberelimab (anti-PD-1 antibody), and casdatifan (HIF-2α inhibitor). The company is also developing earlier-stage candidates including AB598 (anti-CD39), AB801 (AXL inhibitor), and an emerging inflammation & immunology portfolio with AB102 (MRGPRX2 antagonist), TNF inhibitor, CCR6 antagonist, and anti-CD89. Arcus focuses on designing rational, biology-driven combination therapies that can be used together to improve cancer treatment outcomes.

Product and service11 records
1Domvanalimab
CategoryClinical Candidate — Oncology Immunotherapy
Description

Fc-silent anti-TIGIT monoclonal antibody designed to block TIGIT and release the brake on immune cells to accelerate anti-cancer immunity. Engineered to avoid peripheral Treg depletion that can lead to autoimmune toxicities.

2Quemliclustat
CategoryClinical Candidate — Adenosine Axis Inhibitor
Description

Small-molecule CD73 inhibitor that blocks the enzymatic conversion of AMP to adenosine, designed to prevent adenosine-mediated immune suppression and trigger cancer cell death.

3Etrumadenant
CategoryClinical Candidate — Adenosine Axis Inhibitor
Description

Small-molecule dual antagonist of A2a and A2b adenosine receptors designed to free immune cells from adenosine suppression to fight cancer, with reduced blood-brain barrier penetration to minimize CNS side effects.

4Zimberelimab
CategoryClinical Candidate — Immune Checkpoint Inhibitor
Description

Monoclonal antibody that binds PD-1, a well-established checkpoint of anti-cancer immunity, used as a combination backbone in Arcus's clinical programs.

5Casdatifan
CategoryClinical Candidate — Targeted Oncology
Description

Small-molecule HIF-2α inhibitor designed to provide deeper and more durable inhibition of the HIF-2α pathway for the treatment of clear cell renal cell carcinoma, with best-in-class potential demonstrated in late-line kidney cancer.

6AB598
CategoryClinical Candidate — Oncology Immunotherapy
Description

Investigational anti-CD39 monoclonal antibody that blocks the CD39 enzyme to preserve ATP in the tumor microenvironment, boosting the ability of immune cells to target cancer cells.

7AB801
CategoryClinical Candidate — Targeted Oncology
Description

Investigational AXL receptor tyrosine kinase inhibitor designed to overcome AXL-mediated therapeutic resistance and reignite responses to standard-of-care therapies.

8AB102
CategoryClinical Candidate — Inflammation and Immunology
Description

MRGPRX2 small-molecule antagonist being developed for potential indications including atopic dermatitis and chronic spontaneous urticaria.

9TNF Inhibitor
CategoryClinical Candidate — Inflammation and Immunology
Description

Small-molecule TNF inhibitor being developed for potential indications including rheumatoid arthritis, psoriasis, and inflammatory bowel disease.

10CCR6 Antagonist
CategoryClinical Candidate — Inflammation and Immunology
Description

Small-molecule CCR6 antagonist being developed for potential indication in psoriasis.

11Anti-CD89
CategoryClinical Candidate — Inflammation and Immunology
Description

Monoclonal antibody being developed for potential indication in rheumatoid arthritis.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Bristol-Myers Squibb
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-03
Description

Arcus announced a clinical trial collaboration with Bristol-Myers Squibb to evaluate casdatifan, an investigational HIF-2α inhibitor, in combination with pumitamig (a PD-L1/VEGFA bispecific immunomodulator) in a Phase 1/2 clinical trial for kidney cancer (renal cell carcinoma).

stocktitan.net
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-19
Description

Taiho Pharmaceutical exercised its option for an exclusive license to develop and commercialize casdatifan in Japan and certain territories in Asia, based on a 2017 collaboration agreement. Taiho also holds rights for domvanalimab, zimberelimab, quemliclustat, and etrumadenant in these regions. Taiho is operationalizing the ongoing Phase 3 PRISM-1 registrational study for quemliclustat and participating in the Phase 3 PEAK-1 registrational study for casdatifan.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-29
Description

Gilead Sciences and Arcus have a broad strategic collaboration on immuno-oncology programs, particularly the TIGIT pathway therapies. In January 2024, Gilead invested an additional $320 million in Arcus, raising its ownership stake to 33%, and gained a seat on Arcus's board. The collaboration focuses on domvanalimab, quemliclustat, etrumadenant, and zimberelimab. Gilead holds commercialization rights outside the US (subject to Taiho's regional rights) and the companies share co-promotion rights in the US.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Arcus and AstraZeneca have a clinical collaboration on PACIFIC-8, a registrational Phase 3 clinical trial evaluating domvanalimab plus durvalumab (Imfinzi) in unresectable Stage 3 non-small cell lung cancer, where durvalumab is the standard of care. AstraZeneca is the sponsor of and is operationalizing this study.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage precision oncology company developing allosteric kinase inhibitors. Similar clinical-stage status, oncology pipeline, and small-molecule approach.

TypeDirect peer
Description

Clinical-stage oncology company developing engineered conditionally activated cytokines (PREDATOR platform). Comparable clinical-stage profile and immuno-oncology pipeline focus.

TypeDirect peer
Description

Clinical-stage precision oncology company developing RAS(ON) inhibitors. Similar clinical-stage profile, oncology focus, and pipeline-of-novel-mechanisms thesis.

TypeDirect peer
Description

Clinical-stage immuno-oncology company developing computationally-discovered drug targets and antibody therapeutics. Similar clinical-stage profile, oncology focus, and pipeline-driven valuation model.

TypeDirect peer
Description

Clinical-stage immuno-oncology company developing TIGIT and adenosine pathway antagonists. Most directly comparable peer given shared TIGIT and adenosine axis programs (acquired by AstraZeneca in 2024).

TypeDirect peer
Description

Precision oncology company developing small molecule inhibitors targeting the RAS/MAPK pathway. Comparable clinical-stage status, oncology pipeline focus, and small-molecule modality.

TypeEmerging player
Description

Computational drug discovery platform with proprietary pipeline and partnerships. Adjacent drug discovery technology focus, though broader platform business model.

TypeDirect peer
Description

Clinical-stage oncology company developing kinase inhibitors for genomically defined cancers. Comparable clinical-stage status and oncology drug development focus.

TypeBroad incumbent
Description

Clinical-to-commercial precision oncology company acquired by Bristol-Myers Squibb in 2024. Relevant precedent for oncology-focused biotech valuation and strategic acquisition interest.

TypeEmerging player
Description

Clinical-stage immuno-oncology company developing immune-stimulating antibody conjugates (ISACs). Adjacent oncology immunotherapy focus with novel mechanism platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors20 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Arcus Biosciences

Immuno-Oncology Therapeuticsarcusbio.com

Arcus Biosciences is a clinical-stage biopharmaceutical company developing small-molecule and antibody cancer therapies — including casdatifan, domvanalimab, and adenosine-axis inhibitors — for oncology patients, with global development and commercialization through partnerships with Gilead, Taiho, AstraZeneca, and BMS.

What Arcus Biosciences does

Arcus Biosciences is a clinical-stage biopharmaceutical company headquartered in Hayward, California, founded in 2015 by Terry Rosen (CEO) and Juan Jaen (President). The company discovers and develops small-molecule inhibitors and monoclonal antibodies targeting cancer biology, with a stated emphasis on rational, biology-driven combination therapies across mechanisms including HIF-2α inhibition (casdatifan), Fc-silent anti-TIGIT (domvanalimab), adenosine axis antagonism (etrumadenant, quemliclustat), anti-PD-1 (zimberelimab), anti-CD39 (AB598), and AXL inhibition (AB801). Arcus employs 501-1,000 people, trades on the NYSE under ticker RCUS, and is expanding an early-stage inflammation and immunology portfolio (AB102/MRGPRX2, TNF inhibitor, CCR6 antagonist, anti-CD89).

The company has no approved products and generates revenue almost entirely from collaboration agreements rather than product sales. Its 2020 collaboration with Gilead Sciences — expanded via a $320 million Gilead equity investment in January 2024 that raised Gilead's stake to 33% — provides co-promotion rights in the US and ex-US commercialization rights for several programs. Taiho Pharmaceutical holds regional rights in Japan and certain Asian territories (excluding China), and AstraZeneca sponsors the registrational PACIFIC-8 Phase 3 trial in Stage 3 NSCLC. Two Phase 3 TIGIT failures (STAR-221 in December 2024 and STAR-121 in April 2026) have triggered a strategic reset: Gilead elected not to make an option continuation payment, prompting a partial rollback of the 2020 collaboration, a ~10% workforce reduction, and a R&D pivot toward casdatifan and inflammation/immunology programs. FY2025 collaboration revenue was $247 million, with cash of approximately $1.0 billion and stated runway into 2H 2028.

Strategically, Arcus is repositioning around casdatifan, supported by a 45% confirmed ORR and 15.1-month median progression-free survival in late-line kidney cancer and a Goldman Sachs risk-adjusted peak sales estimate of $1.7 billion in clear cell RCC. A new Bristol-Myers Squibb clinical collaboration (June 2026) combines casdatifan with pumitamig in RCC. Capital formation in 2025 — a $150 million public offering in February and a $250 million public offering in October — combined with a $250 million Hercules Capital term loan facility (August 2024, $50M drawn at close) funds Phase 3 execution. The company's competitive position rests on differentiated molecular design (notably Fc-silent TIGIT and HIF-2α chemistry), a leadership team with deep prior pharma R&D experience, and a partner ecosystem with Gilead, Taiho, AstraZeneca, and BMS; its principal risks are TIGIT program failures, revenue concentration on Gilead, and execution risk on casdatifan pivotal trials.

Arcus Biosciences firmographics

Firmographics
Name
Arcus Biosciences
Legal name
Arcus Biosciences, Inc.
Website
https://arcusbio.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Arcus Biosciences is a clinical-stage biopharmaceutical company developing small-molecule and antibody cancer therapies — including casdatifan, domvanalimab, and adenosine-axis inhibitors — for oncology patients, with global development and commercialization through partnerships with Gilead, Taiho, AstraZeneca, and BMS.
Ownership category
akta.pro rank

Arcus Biosciences industry classification

Industry
Product category
Immuno-Oncology Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
akta.pro industry
PRIMARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAAAK
Therapeutic Enzymes & Enzyme Replacement Therapies (ERT)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)

Keywords

  • Cancer immunotherapy
  • Monoclonal antibody therapy
  • Small molecule inhibitors
  • Immuno-oncology drugs
  • Clinical-stage biopharmaceuticals

Where Arcus Biosciences is headquartered

Location

Headquarters

HQ city
Hayward
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Arcus Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Collaboration Revenue: Revenue from Gilead Sciences collaboration, including $320M equity investment and potential milestone payments. The company reported $247M full-year 2025 revenues driven primarily by its collaboration with Gilead.
  2. Licensing and Milestone Payments: Revenue from licensing agreements including Taiho Pharmaceutical exercising option for exclusive license to casdatifan in Japan and Asia, with potential payments and royalties.
  3. Future Product Sales: Once approved, the company will commercialize products directly in the US (with Gilead co-promotion rights) and through partners internationally.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Arcus Biosciences product offering

Product offering

Core offering

Arcus Biosciences is a clinical-stage biopharmaceutical company that discovers, develops, and intends to commercialize novel small molecule inhibitors and monoclonal antibodies for the treatment of cancer. Its pipeline is built around multiple differentiated mechanisms, including Fc-silent anti-TIGIT antibodies, HIF-2α inhibition, adenosine axis blockade (A2a/A2b antagonism and CD73 inhibition), anti-PD-1, anti-CD39, and AXL inhibition, with an emerging inflammation and immunology portfolio.

Product overview

Arcus Biosciences is a clinical-stage biopharmaceutical company developing best-in-class molecules and combination therapies for cancer treatment. The company's clinical pipeline includes multiple investigational candidates: domvanalimab (Fc-silent anti-TIGIT antibody), quemliclustat (CD73 inhibitor), etrumadenant (A2a/A2b adenosine receptor antagonist), zimberelimab (anti-PD-1 antibody), and casdatifan (HIF-2α inhibitor). The company is also developing earlier-stage candidates including AB598 (anti-CD39), AB801 (AXL inhibitor), and an emerging inflammation & immunology portfolio with AB102 (MRGPRX2 antagonist), TNF inhibitor, CCR6 antagonist, and anti-CD89. Arcus focuses on designing rational, biology-driven combination therapies that can be used together to improve cancer treatment outcomes.

Differentiator

Problem solved

Functional benefit

Products and services

  • Domvanalimab Fc-silent anti-TIGIT monoclonal antibody designed to block TIGIT and release the brake on immune cells to accelerate anti-cancer immunity. Engineered to avoid peripheral Treg depletion that can lead to autoimmune toxicities.
  • Quemliclustat Small-molecule CD73 inhibitor that blocks the enzymatic conversion of AMP to adenosine, designed to prevent adenosine-mediated immune suppression and trigger cancer cell death.
  • Etrumadenant Small-molecule dual antagonist of A2a and A2b adenosine receptors designed to free immune cells from adenosine suppression to fight cancer, with reduced blood-brain barrier penetration to minimize CNS side effects.
  • Zimberelimab Monoclonal antibody that binds PD-1, a well-established checkpoint of anti-cancer immunity, used as a combination backbone in Arcus's clinical programs.
  • Casdatifan Small-molecule HIF-2α inhibitor designed to provide deeper and more durable inhibition of the HIF-2α pathway for the treatment of clear cell renal cell carcinoma, with best-in-class potential demonstrated in late-line kidney cancer.
  • AB598 Investigational anti-CD39 monoclonal antibody that blocks the CD39 enzyme to preserve ATP in the tumor microenvironment, boosting the ability of immune cells to target cancer cells.
  • AB801 Investigational AXL receptor tyrosine kinase inhibitor designed to overcome AXL-mediated therapeutic resistance and reignite responses to standard-of-care therapies.
  • AB102 MRGPRX2 small-molecule antagonist being developed for potential indications including atopic dermatitis and chronic spontaneous urticaria.
  • TNF Inhibitor Small-molecule TNF inhibitor being developed for potential indications including rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
  • CCR6 Antagonist Small-molecule CCR6 antagonist being developed for potential indication in psoriasis.
  • Anti-CD89 Monoclonal antibody being developed for potential indication in rheumatoid arthritis.

Companies that use Arcus Biosciences

Customer profile

Named customers2 records

Segments1 record

Ideal customer profiles1 record

Arcus Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Arcus Biosciences partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Bristol-Myers SquibbcoreStrategic or Co-development Partner · 3 June 2026Arcus announced a clinical trial collaboration with Bristol-Myers Squibb to evaluate casdatifan, an investigational HIF-2α inhibitor, in combination with pumitamig (a PD-L1/VEGFA bispecific immunomodulator) in a Phase 1/2 clinical trial for kidney cancer (renal cell carcinoma).
  • Taiho PharmaceuticalcoreStrategic or Co-development Partner · 19 October 2025Taiho Pharmaceutical exercised its option for an exclusive license to develop and commercialize casdatifan in Japan and certain territories in Asia, based on a 2017 collaboration agreement. Taiho also holds rights for domvanalimab, zimberelimab, quemliclustat, and etrumadenant in these regions. Taiho is operationalizing the ongoing Phase 3 PRISM-1 registrational study for quemliclustat and participating in the Phase 3 PEAK-1 registrational study for casdatifan.
  • Gilead SciencescoreStrategic or Co-development Partner · 29 January 2024Gilead Sciences and Arcus have a broad strategic collaboration on immuno-oncology programs, particularly the TIGIT pathway therapies. In January 2024, Gilead invested an additional $320 million in Arcus, raising its ownership stake to 33%, and gained a seat on Arcus's board. The collaboration focuses on domvanalimab, quemliclustat, etrumadenant, and zimberelimab. Gilead holds commercialization rights outside the US (subject to Taiho's regional rights) and the companies share co-promotion rights in the US.
  • AstraZenecacoreStrategic or Co-development PartnerArcus and AstraZeneca have a clinical collaboration on PACIFIC-8, a registrational Phase 3 clinical trial evaluating domvanalimab plus durvalumab (Imfinzi) in unresectable Stage 3 non-small cell lung cancer, where durvalumab is the standard of care. AstraZeneca is the sponsor of and is operationalizing this study.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Arcus Biosciences competitors and assessment

Company assessment

Direct peers

  • Black Diamond Therapeutics: Clinical-stage precision oncology company developing allosteric kinase inhibitors. Similar clinical-stage status, oncology pipeline, and small-molecule approach.
  • Werewolf Therapeutics: Clinical-stage oncology company developing engineered conditionally activated cytokines (PREDATOR platform). Comparable clinical-stage profile and immuno-oncology pipeline focus.
  • Revolution Medicines: Clinical-stage precision oncology company developing RAS(ON) inhibitors. Similar clinical-stage profile, oncology focus, and pipeline-of-novel-mechanisms thesis.
  • Compugen: Clinical-stage immuno-oncology company developing computationally-discovered drug targets and antibody therapeutics. Similar clinical-stage profile, oncology focus, and pipeline-driven valuation model.
  • iTeos Therapeutics: Clinical-stage immuno-oncology company developing TIGIT and adenosine pathway antagonists. Most directly comparable peer given shared TIGIT and adenosine axis programs (acquired by AstraZeneca in 2024).
  • Erasca: Precision oncology company developing small molecule inhibitors targeting the RAS/MAPK pathway. Comparable clinical-stage status, oncology pipeline focus, and small-molecule modality.
  • Cogent Biosciences: Clinical-stage oncology company developing kinase inhibitors for genomically defined cancers. Comparable clinical-stage status and oncology drug development focus.

Emerging players

  • Schrödinger: Computational drug discovery platform with proprietary pipeline and partnerships. Adjacent drug discovery technology focus, though broader platform business model.
  • Bolt Biotherapeutics: Clinical-stage immuno-oncology company developing immune-stimulating antibody conjugates (ISACs). Adjacent oncology immunotherapy focus with novel mechanism platform.

Broad incumbents

  • Mirati Therapeutics: Clinical-to-commercial precision oncology company acquired by Bristol-Myers Squibb in 2024. Relevant precedent for oncology-focused biotech valuation and strategic acquisition interest.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Arcus Biosciences social profiles

Digital presence

Arcus Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Arcus Biosciences leadership team

Management profile

Number of profiles

Profiles8 records

Arcus Biosciences funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors20 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Arcus Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arcus Biosciences

What does Arcus Biosciences do?

Arcus Biosciences is a clinical-stage biopharmaceutical company that discovers, develops, and intends to commercialize novel small molecule inhibitors and monoclonal antibodies for the treatment of cancer. Its pipeline is built around multiple differentiated mechanisms, including Fc-silent anti-TIGIT antibodies, HIF-2α inhibition, adenosine axis blockade (A2a/A2b antagonism and CD73 inhibition), anti-PD-1, anti-CD39, and AXL inhibition, with an emerging inflammation and immunology portfolio.

Is Arcus Biosciences a public or private company?

Arcus Biosciences is a public company. It is classified as public and is currently operating.

When was Arcus Biosciences founded?

Arcus Biosciences was founded in 2015. It employs 501 to 1,000 people.

Where is Arcus Biosciences based?

Arcus Biosciences is headquartered in Hayward, United States, in the North America region.

How does Arcus Biosciences make money?

Three revenue lines are on record. Collaboration Revenue is the primary driver. The others are licensing and Milestone Payments and future Product Sales.

Who are Arcus Biosciences's main competitors?

Direct peers on record are Black Diamond Therapeutics, Werewolf Therapeutics, Revolution Medicines, Compugen, iTeos Therapeutics, Erasca and Cogent Biosciences. Emerging players are Schrödinger and Bolt Biotherapeutics. Mirati Therapeutics is listed as a broad incumbent.

Does Arcus Biosciences have an API?

No public API is recorded for Arcus Biosciences.

What industry is Arcus Biosciences in?

Arcus Biosciences's product category is Immuno-Oncology Therapeutics. Its primary akta.pro industry code is HLAAACAF, Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches), with a secondary code of HLAAAAAK, Therapeutic Enzymes & Enzyme Replacement Therapies (ERT). Its NAICS code is 325414.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogArcus Biosciences to Participate in Two Upcoming Investor ConferencesArcus Biosciences announced its management team will participate in two investor conferences in December: the Evercore Healthcare Conference on December 1st and Citi's Global Healthcare Conference on December 2nd, both in Florida. The company will host fireside chats and 1x1 meetings, with live webcasts available on its website.Stock TitanArcus Biosciences to join two investor conferences Dec. 1-2Arcus Biosciences announced its management team will participate in two investor conferences in December: the Evercore Healthcare Conference on Dec. 1 in Coral Gables, FL, and Citi's Global Healthcare Conference on Dec. 2 in Miami, FL. Both events include fireside chats and 1x1 meetings, with live webcasts available on the company's website.FinancialContent Business PageArcus Biosciences to Participate in Two Upcoming Investor ConferencesArcus Biosciences announced its management team will participate in two investor conferences in December: the Evercore Healthcare Conference on December 1st and Citi's Global Healthcare Conference on December 2nd, both in Florida. The company will host fireside chats and 1x1 meetings, with live webcasts available on its website.TIKRA $7.9 Billion Fund Dumps These 3 StocksMontanova Capital, managing $7.87 billion, sold all its Advanced Micro Devices, Arcus Biosciences, and Ferguson Enterprises shares by Sept. 30. AMD fell 13% since the quarter ended, Arcus fell 47%, and Ferguson rose 5%. Analysts' consensus targets are 31% above AMD, 150% above Arcus, and 17% above Ferguson.Investing.comArcus Biosciences at Jefferies Global Healthcare Conference: casdatifan pushArcus Biosciences presented its casdatifan program at Jefferies' healthcare conference, citing stronger and longer HIF-2α inhibition than belzutifan. The company expects PEAK-1 enrollment to finish in one to two months with a readout in early 2028, and frontline phase III testing to begin by year-end 2024. It sees a $5–10 billion peak sales opportunity and cash runway into 2029.American Banking and Market NewsArcus Biosciences, Inc. $RCUS Stock: Candriam S.C.A. Trims PositionCandriam S.C.A. reduced its Arcus Biosciences stake by 18.9% in Q3, selling 125,158 shares. Arcus reported Q3 EPS of -$1.00, missing estimates, with revenue down 65.4% year-over-year. Analysts rate the stock a Moderate Buy with an average price target of $39.36.Defense WorldArcus Biosciences (NYSE:RCUS) Price Target Raised to $49.00Leerink Partners raised Arcus Biosciences' price target to $49 from $46, keeping an outperform rating. The company reported a Q3 loss of $1.00 per share, missing the $0.89 consensus, while revenue of $9 million beat expectations but fell 65.4% year over year.Simply Wall StArcus Biosciences (RCUS) Could Be 55% Undervalued As Third Quarter Losses LandArcus Biosciences reported Q3 revenue of $9 million and a net loss of $128 million. The company's shares closed at $18.28, with a fair value estimate of $41, implying a 55% undervaluation. The valuation hinges on the kidney cancer drug casdatifan's late-stage trial results.American Banking and Market NewsArcus Biosciences (NYSE:RCUS) Price Target Cut to $45.00 by Analysts at WedbushWedbush cut Arcus Biosciences' price target to $45 from $49, keeping an outperform rating. The company reported a Q3 loss of $1.00 per share, missing the $0.89 consensus, with revenue of $9 million down 65.4% year-over-year. Analysts forecast a -3.55 EPS for the current fiscal year.